

## CURRICULUM VITAE

Benjamin Y. Lu, MD, PhD

Version Date: 7/12/2026

### Contact Information:

Address 300 George Street  
Rm 353J  
New Haven, CT 06511  
Phone: 1 (203) 710-9005  
Email: benjamin.lu@yale.edu

School: Yale School of Medicine

### Education:

08/2007 - 05/2011 BS, Rice University, Houston, TX  
08/2011 - 05/2015 MD, New York University, New York, NY  
07/2020 - 12/2024 PhD, Yale University, Investigative Medicine, New Haven, CT

### Career/Academic Appointments:

07/2016 - 06/2019 Residency, Internal Medicine, Yale New Haven Hospital, New Haven, CT  
07/2019 - 06/2023 Clinical Fellow, Medical Oncology and Hematology, Yale School of Medicine, New Haven, CT  
07/2019 - 06/2022 Fellowship, Medical Oncology, Yale Cancer Center, New Haven, CT  
06/2021 - 06/2022 Chief Fellow, Medical Oncology / Hematology, Yale Cancer Center, New Haven, CT  
07/2022 - 06/2023 Postdoctoral Fellow, Medical Oncology, Yale School of Medicine, New Haven, CT  
07/2023 - 06/2024 Associate Research Scientist, Medical Oncology and Hematology, Yale School of Medicine, New Haven, CT  
07/2024 - 06/2025 Instructor, Medical Oncology and Hematology, Yale School of Medicine, New Haven, CT  
07/2025 - 06/2028 Assistant Professor, Medical Oncology and Hematology, Yale School of Medicine, New Haven, CT

### Administrative Positions:

2019 - 2023 Clinical Fellow, Medical Oncology, Yale School of Medicine, New Haven, CT  
2021 - 2022 Chief Fellow, Medical Oncology, Hematology, Yale School of Medicine, New Haven, CT  
2021 - 2023 T32 Post-doctoral Fellow, Yale School of Medicine, New Haven, CT

|                |                                                                                                                       |
|----------------|-----------------------------------------------------------------------------------------------------------------------|
| 2025 - 2027    | Kathryn Louloudis Scholar in Cancer Research, Medical Oncology and Hematology, Yale School of Medicine, New Haven, CT |
| 2026 - Present | Core Faculty, Medical Oncology and Hematology, Yale School of Medicine, New Haven, CT                                 |

#### Board Certification:

|             |                                            |
|-------------|--------------------------------------------|
| 2020 - 2025 | AB of Internal Medicine, Internal Medicine |
| 2022 - 2025 | AB of Internal Medicine, Medical Oncology  |

#### Professional Honors & Recognition:

##### International/National/Regional

|      |                                                                                                         |
|------|---------------------------------------------------------------------------------------------------------|
| 2012 | Medical Student Summer Fellowship, American Brain Tumor Association (ABTA)                              |
| 2012 | Medical Student Summer Research Fellowship, American Academy of Neurological Surgeons (AANS)            |
| 2012 | Lucien Rubinstein Award, American Brain Tumor Association (ABTA)                                        |
| 2021 | Young Investigator Award, Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) |
| 2021 | T32 Ruth L. Kirschstein National Research Service Award, National Cancer Institute                      |
| 2023 | K12 Paul Calabresi Career Development Award for Clinical Oncology, National Cancer Institute            |
| 2025 | Emerging-Generation Award, American Society of Clinical Investigation (ASCI)                            |
| 2025 | Career Development Award, Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) |
| 2026 | Clinician Scientist Development Grant, American Cancer Society                                          |

##### Yale University/Yale School of Medicine/Hospital System

|      |                                                                                 |
|------|---------------------------------------------------------------------------------|
| 2018 | Excellence in Education Research, Yale School of Medicine                       |
| 2019 | Outstanding Yale Traditional Resident Award, West Haven VA Center of Excellence |
| 2025 | Iva Dostanic, MD, PhD Physician-Scientist Trainee Award, Yale University        |
| 2025 | Career Enhancement Program Grant, Yale SPORE in Lung Cancer                     |
| 2025 | Kathryn Louloudis Scholar in Cancer Research, Yale Cancer Center                |

##### Other

|      |                                                                                              |
|------|----------------------------------------------------------------------------------------------|
| 2009 | George R. Brown Undergraduate Research Fellowship, Rice University                           |
| 2010 | Klaus and Eugenia Weissenberger Award , Hanszen College                                      |
| 2010 | Outstanding Bioengineering Junior Award, Rice University                                     |
| 2011 | Rice Engineering Alumni Research Excellence Award, Rice Engineering Alumni                   |
| 2011 | Grand Prize at the Brown School of Engineering Design Showcase, Rice University              |
| 2011 | Outstanding Bioengineering Senior Design Project Award, Rice University                      |
| 2011 | Beyond Traditional Borders Innovator Award, Rice360 Institute for Global Health Technologies |

|      |                                                                                            |
|------|--------------------------------------------------------------------------------------------|
| 2011 | Outstanding Bioengineering Senior Award, Rice University                                   |
| 2011 | Cum laude, Rice University                                                                 |
| 2015 | Honors in Research, New York University                                                    |
| 2016 | Outstanding Intern Teaching Award, Massachusetts General Hospital / Harvard Medical School |

## Grants/Clinical Trials History:

### Current Grants

|                 |                                                                                                                                                           |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|
| Agency:         | National Cancer Institute                                                                                                                                 |
| I.D.#:          | 5R01CA266757                                                                                                                                              |
| Title:          | Targeting T cell dysfunction in glioblastoma: A proof-of-concept Phase 0/I trial of anti-TIGIT antibody AB154 in combination with anti-PD1 antibody AB122 |
| P.I.:           | David A. Hafler                                                                                                                                           |
| Role:           | Key Personnel                                                                                                                                             |
| Percent effort: | 10%                                                                                                                                                       |
| Total costs:    | \$648,555.00 (of which \$254,317.00 indirects)                                                                                                            |
| Project period: | 02/15/2022                                                                                                                                                |
| Agency:         | American Cancer Society                                                                                                                                   |
| I.D.#:          | Clinician Scientist Development Grant                                                                                                                     |
| Title:          | Effects of anti-TIGIT and anti-PD-1 on regulatory T cells and cancer cells in human glioblastoma                                                          |
| Role:           | Principal Investigator                                                                                                                                    |
| Percent effort: | 66%                                                                                                                                                       |
| Total costs:    | \$750,000.00 (of which \$75,000.00 indirects)                                                                                                             |
| Project period: | 04/01/2026 - 08/31/2030                                                                                                                                   |
| Agency:         | American Society of Clinical Oncology Foundation                                                                                                          |
| I.D.#:          | Career Development Award                                                                                                                                  |
| Title:          | Overcoming hypoxia-dependent mechanisms of immune checkpoint resistance                                                                                   |
| Role:           | Principal Investigator                                                                                                                                    |
| Percent effort: | 29%                                                                                                                                                       |
| Total costs:    | \$200,000.00 (of which \$10,600.00 indirects)                                                                                                             |
| Project period: | 07/01/2025 - 06/30/2028                                                                                                                                   |
| Agency:         | Yale SPORE in Lung Cancer                                                                                                                                 |
| I.D.#:          | Career Enhancement Program Award                                                                                                                          |
| Title:          | Malignant pleural effusion-derived T cells for adoptive cell therapy in non-small cell lung cancer                                                        |
| P.I.:           | Gavitt Woodard                                                                                                                                            |
| Role:           | Principal Investigator                                                                                                                                    |
| Percent effort: | N/A                                                                                                                                                       |
| Total costs:    | \$50,000.00                                                                                                                                               |

Project period: 08/01/2025 - 07/31/2026

### Current Clinical Trials

Agencies: Yale Cancer Center  
 I.D.#: 1206010419  
 Title: Yale Head and Neck Tissue Biorepository  
 P.I.: Ansley Roche  
 Role: Sub-Investigator  
 Percent effort: N/A  
 Total costs: -  
 Project period: 07/27/2012 - ongoing

Agencies: Yale Cancer Center  
 I.D.#: 2000021359REG  
 Title: Biospecimen and Data Repository for Cerebrotropic Cancers  
 P.I.: Harriet Kluger  
 Role: Sub-Investigator  
 Percent effort: N/A  
 Total costs: -  
 Project period: 08/23/2017 - ongoing

Agencies: National Cancer Institute (NCI)  
 I.D.#: 2000023741REG  
 Title: Cerebrospinal Fluid Collection Repository  
 P.I.: Veronica Chiang  
 Role: Sub-Investigator  
 Percent effort: N/A  
 Total costs: -  
 Project period: 10/17/2018 - ongoing

Agencies: Alliance for Clinical Trials in Oncology  
 I.D.#: 2000028827  
 Title: Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)  
 P.I.: Ashita Talsania  
 Role: Sub-Investigator  
 Percent effort: N/A  
 Total costs: -  
 Project period: 05/25/2020 - ongoing

Agencies: NRG Oncology  
 I.D.#: 2000033846  
 Title: RANdomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial

P.I.: Henry S. Park  
 Role: Sub-Investigator  
 Percent effort: N/A  
 Total costs: -  
 Project period: 03/13/2023 - ongoing

Agencies: ORIC Pharmaceuticals, Inc.  
 I.D.#: 2000035136  
 Title: An Open-Label, Phase 1/1b, Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

P.I.: Sarah Goldberg  
 Role: Sub-Investigator  
 Percent effort: N/A  
 Total costs: -  
 Project period: 08/28/2023 - ongoing

Agencies: SyntheKine, Inc.  
 I.D.#: 2000034639  
 Title: A Phase 1a/1b Study to Evaluate the Safety and Tolerability of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

P.I.: So Yeon Kim  
 Role: Sub-Investigator  
 Percent effort: N/A  
 Total costs: -  
 Project period: 11/01/2023 - ongoing

Agencies: Genentech, Inc.  
 I.D.#: 2000035312  
 Title: NAUTIKA1: Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer

P.I.: So Yeon Kim  
 Role: Sub-Investigator  
 Percent effort: N/A  
 Total costs: -  
 Project period: 11/10/2023 - ongoing

Agencies: Hoffmann (F) - La Roche, Ltd  
 I.D.#: 2000035521  
 Title: A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

P.I.: Sarah Goldberg  
 Role: Sub-Investigator  
 Percent effort: N/A  
 Total costs: -  
 Project period: 01/22/2024 - ongoing

Agencies: Eli Lilly and Company  
 I.D.#: 2000036799  
 Title: SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression  $\geq 50\%$  or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression

P.I.: So Yeon Kim  
 Role: Sub-Investigator  
 Percent effort: N/A  
 Total costs: -  
 Project period: 05/20/2024 - ongoing

Agencies: AstraZeneca Pharmaceutical LP  
 I.D.#: 2000036026  
 Title: A Phase I, Multicenter, Open-label, First-in Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Tumors

P.I.: Sarah Goldberg  
 Role: Sub-Investigator  
 Percent effort: N/A  
 Total costs: -  
 Project period: 05/22/2024 - ongoing

Agencies: Zai Laboratory  
 I.D.#: 2000038196  
 Title: A Study of ZL-1310 in Patients With Small Cell Lung Cancer  
 P.I.: Anne Chiang  
 Role: Sub-Investigator  
 Percent effort: N/A  
 Total costs: -  
 Project period: 10/29/2024 - ongoing

Agencies: SystImmune, Inc.  
 I.D.#: 2000038514  
 Title: Study to Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

P.I.: Scott Gettinger  
 Role: Sub-Investigator  
 Percent effort: N/A  
 Total costs: -  
 Project period: 11/07/2024 - ongoing

Agencies: Janssen Research & Development, LLC  
 I.D.#: 2000038922  
 Title: A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination With Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination With Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

P.I.: Sarah Goldberg  
 Role: Sub-Investigator  
 Percent effort: N/A  
 Total costs: -  
 Project period: 12/03/2024 - ongoing

Agencies: AstraZeneca Pharmaceutical LP  
 I.D.#: 2000039473  
 Title: A Phase III, Open-label, Randomised Study of Osimertinib With or Without Datopotamab Deruxtecan (Dato-DXd), as First-line Treatment in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer

P.I.: Sarah Goldberg  
 Role: Sub-Investigator  
 Percent effort: N/A  
 Total costs: -  
 Project period: 03/24/2025 - ongoing

Agencies: Summit Therapeutics  
 I.D.#: 2000039870  
 Title: SMT112-3003: A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer (HARMONi-3) [Advarra IRB]

P.I.: Benjamin Newton  
 Role: Sub-Investigator  
 Percent effort: N/A  
 Total costs: -  
 Project period: 06/23/2025 - ongoing

Agencies: Revolution Medicines, Inc.

|                 |                                                                                                                                                                                                                                                                          |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| I.D.#:          | 2000040314                                                                                                                                                                                                                                                               |
| Title:          | RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC                                                                                            |
| P.I.:           | So Yeon Kim                                                                                                                                                                                                                                                              |
| Role:           | Sub-Investigator                                                                                                                                                                                                                                                         |
| Percent effort: | N/A                                                                                                                                                                                                                                                                      |
| Total costs:    | -                                                                                                                                                                                                                                                                        |
| Project period: | 08/20/2025 - ongoing                                                                                                                                                                                                                                                     |
|                 |                                                                                                                                                                                                                                                                          |
| Agencies:       | CatalYm GmbH                                                                                                                                                                                                                                                             |
| I.D.#:          | 2000039721                                                                                                                                                                                                                                                               |
| Title:          | A Phase 2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab Versus Placebo, in Combination With Pembrolizumab, Pemetrexed, and Carboplatin, in 1L Treatment of Participants With Metastatic NSCLC (GDFATHER-NSCLC-01)   |
| P.I.:           | Sarah Goldberg                                                                                                                                                                                                                                                           |
| Role:           | Sub-Investigator                                                                                                                                                                                                                                                         |
| Percent effort: | N/A                                                                                                                                                                                                                                                                      |
| Total costs:    | -                                                                                                                                                                                                                                                                        |
| Project period: | 08/29/2025 - ongoing                                                                                                                                                                                                                                                     |
|                 |                                                                                                                                                                                                                                                                          |
| Agencies:       | Merck Sharp & Dohme LLC                                                                                                                                                                                                                                                  |
| I.D.#:          | 2000039588                                                                                                                                                                                                                                                               |
| Title:          | A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTTerpath-009) |
| P.I.:           | So Yeon Kim                                                                                                                                                                                                                                                              |
| Role:           | Sub-Investigator                                                                                                                                                                                                                                                         |
| Percent effort: | N/A                                                                                                                                                                                                                                                                      |
| Total costs:    | -                                                                                                                                                                                                                                                                        |
| Project period: | 09/10/2025 - ongoing                                                                                                                                                                                                                                                     |
|                 |                                                                                                                                                                                                                                                                          |
| Agencies:       | Amgen, Inc.                                                                                                                                                                                                                                                              |
| I.D.#:          | 2000040758                                                                                                                                                                                                                                                               |
| Title:          | A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination With Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)                   |
| P.I.:           | Anne Chiang                                                                                                                                                                                                                                                              |
| Role:           | Sub-Investigator                                                                                                                                                                                                                                                         |
| Percent effort: | N/A                                                                                                                                                                                                                                                                      |
| Total costs:    | -                                                                                                                                                                                                                                                                        |

Project period: 09/22/2025 - ongoing

Agencies: Janssen Research & Development, LLC  
 I.D.#: 2000040874  
 Title: A Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination With Chemoradiation Followed by Durvalumab in Locally Advanced and Unresectable Stage III NSCLC  
 P.I.: Henry S. Park  
 Role: Sub-Investigator  
 Percent effort: N/A  
 Total costs: -  
 Project period: 11/14/2025 - ongoing

Agencies: Yale Cancer Center  
 I.D.#: 2000039106  
 Title: Iadademstat and Radiation Therapy With Atezolizumab in Extensive Stage Small-cell Lung Cancer (ES-SCLC) Patients With Persistent, Recurrent or Progressive Disease After First Line Systemic Therapy  
 P.I.: Anne Chiang  
 Role: Sub-Investigator  
 Percent effort: N/A  
 Total costs: -  
 Project period: 12/02/2025 - ongoing

Agencies: BlossomHill Therapeutics, Inc.  
 I.D.#: 2000040854  
 Title: A Phase 1/2 Open-Label, Multicenter, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BH-30643 in Adult Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (SOLARA)  
 P.I.: Sarah Goldberg  
 Role: Sub-Investigator  
 Percent effort: N/A  
 Total costs: -  
 Project period: 12/11/2025 - ongoing

Agencies: BioNTech SE  
 I.D.#: 2000040887  
 Title: A Phase Ib/II, Multi-site, Open-label, Dose Finding Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT326 in Combination With BNT327 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)  
 P.I.: Scott Gettinger  
 Role: Sub-Investigator  
 Percent effort: N/A

|                 |                                                                                                                                                                                                                                   |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Total costs:    | -                                                                                                                                                                                                                                 |
| Project period: | 12/11/2025 - ongoing                                                                                                                                                                                                              |
|                 |                                                                                                                                                                                                                                   |
| Agencies:       | Southwest Oncology Group (SWOG)                                                                                                                                                                                                   |
| I.D.#:          | 2000041308                                                                                                                                                                                                                        |
| Title:          | S2409: PRISM: PREcision in SCLC via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC) [NCI CIRB] |
| P.I.:           | Anne Chiang                                                                                                                                                                                                                       |
| Role:           | Sub-Investigator                                                                                                                                                                                                                  |
| Percent effort: | N/A                                                                                                                                                                                                                               |
| Total costs:    | -                                                                                                                                                                                                                                 |
| Project period: | 01/30/2026 - ongoing                                                                                                                                                                                                              |
|                 |                                                                                                                                                                                                                                   |
| Agencies:       | Zai Laboratory                                                                                                                                                                                                                    |
| I.D.#:          | 2000041311                                                                                                                                                                                                                        |
| Title:          | A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-Drug Conjugate (ADC), Compared to Investigator's Choice Therapy in Participants With Relapsed Small Cell Lung Cancer                                          |
| P.I.:           | Anne Chiang                                                                                                                                                                                                                       |
| Role:           | Sub-Investigator                                                                                                                                                                                                                  |
| Percent effort: | N/A                                                                                                                                                                                                                               |
| Total costs:    | -                                                                                                                                                                                                                                 |
| Project period: | 02/17/2026 - ongoing                                                                                                                                                                                                              |
|                 |                                                                                                                                                                                                                                   |
| Agencies:       | Fortvita Biologics (USA), Inc.                                                                                                                                                                                                    |
| I.D.#:          | 2000041427                                                                                                                                                                                                                        |
| Title:          | A Phase 2, Open-label, Multicenter Study of IBI363 (PD1-IL2m) in Subjects with Advanced Solid Malignancies                                                                                                                        |
| P.I.:           | So Yeon Kim                                                                                                                                                                                                                       |
| Role:           | Sub-Investigator                                                                                                                                                                                                                  |
| Percent effort: | N/A                                                                                                                                                                                                                               |
| Total costs:    | -                                                                                                                                                                                                                                 |
| Project period: | 02/20/2026 - ongoing                                                                                                                                                                                                              |
|                 |                                                                                                                                                                                                                                   |
| Agencies:       | Cogent Biosciences, Inc.                                                                                                                                                                                                          |
| I.D.#:          | 2000041727                                                                                                                                                                                                                        |
| Title:          | A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors                                                                                                                                          |
| P.I.:           | Sarah Goldberg                                                                                                                                                                                                                    |
| Role:           | Sub-Investigator                                                                                                                                                                                                                  |
| Percent effort: | N/A                                                                                                                                                                                                                               |
| Total costs:    | -                                                                                                                                                                                                                                 |

Project period: 02/25/2026 - ongoing

Agencies: Merck Sharp & Dohme LLC  
 I.D.#: 2000042280  
 Title: A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)  
 P.I.: Gavitt Woodard  
 Role: Sub-Investigator  
 Percent effort: N/A  
 Total costs: -  
 Project period: 05/20/2026 - ongoing

### Past Grants

Agency: National Cancer Institute  
 I.D.#: 5P50CA121974-15-8454  
 Title: Project 2- Liquid Biopsies for Melanoma that Metastasizes to Inaccessible Sites  
 P.I.: David A. Hafler  
 Role: Key Personnel  
 Percent effort: N/A  
 Total costs: \$294,426.00 (of which \$118,711.00 indirects)  
 Project period: 09/01/2022 - 08/31/2023

Agency: National Institute of Allergy and Infectious Diseases  
 I.D.#: 2P01AI039671  
 Title: Costimulatory Mechanisms of Autoimmunity  
 P.I.: David A. Hafler  
 Role: Key Personnel  
 Percent effort: N/A  
 Total costs: \$2,548,048.00 (of which \$432,000.00 indirects)  
 Project period: 05/09/2023 - 04/30/2025

Agency: National Cancer Institute  
 I.D.#: 5T32CA233414  
 Title: Yale Cancer Center Advanced Training Program for Physician-Scientists (YCC-ATPP)  
 P.I.: Roy S. Herbst  
 Role: Subaward PI  
 Percent effort: 100%  
 Total costs: \$306,652.00 (of which \$25,087.00 indirects)  
 Project period: 08/01/2022 - 07/31/2023

Agency: National Cancer Institute  
 I.D.#: 5K12CA215110

Title: The Yale Cancer Center Calabresi Immuno-Oncology Training Program (IOTP)  
 P.I.: Harriet Kluger  
 Role: Subaward PI  
 Percent effort: 90%  
 Total costs: \$709,775.00  
 Project period: 07/01/2023 - 09/30/2025

Agency: American Society of Clinical Oncology  
 I.D.#: Young Investigator Award  
 Title: Single-cell Characterization of T cells in Radiation Necrosis of Brain Metastases  
 P.I.: Benjamin Lu  
 Role: PI  
 Percent effort: 1%  
 Total costs: \$50,000.00 (of which \$47,500.00 indirects)  
 Project period: 07/01/2021 - 06/30/2022

### Pending Grants

Agency: National Cancer Institute  
 I.D.#: K08 (PA-24-182)  
 Title: Modulating regulatory T cell and cancer cell plasticity through TIGIT and PD-1 blockade in human glioblastoma  
 Role: Principal Investigator  
 Percent effort: 75%  
 Total costs: \$1,728,445.00 (of which \$126,367.00 indirects)  
 Project period: 08/01/2026 - 07/31/2031

Agency: Yale Cancer Center  
 I.D.#: Yale Cancer Center Pilot Grant  
 Title: Evaluating tumor intrinsic cGAS-STING pathways in a pre-clinical, brain metastasis model of radiation necrosis  
 P.I.: Thomas Hayman  
 Role: Principal Investigator  
 Percent effort: N/A  
 Total costs: \$60,000.00  
 Project period: 08/01/2026 - 07/31/2027

### Pending Clinical Trials

Agencies: AbbVie, Inc.  
 I.D.#: 2000039330  
 Title: A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab Vedotin Regimens in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

P.I.: So Yeon Kim  
 Role: Sub-Investigator  
 Percent effort: N/A  
 Total costs: -  
 Project period: 04/08/2025 - ongoing

Agencies: AbbVie, Inc.  
 I.D.#: 2000041188  
 Title: A Phase 2 Randomized, Open Label, Multicenter Study to Evaluate the Optimal Dose, Safety, and Efficacy of ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Subjects With Previously Untreated Extensive Stage Small Cell Lung Cancer (ES-SCLC)

P.I.: Anne Chiang  
 Role: Sub-Investigator  
 Percent effort: N/A  
 Total costs: -  
 Project period: 01/23/2026 - ongoing

## Invited Speaking Engagements, Presentations & Workshops Not Affiliated With Yale:

### International/National

1. "Thinking Global – Lessons From Swaziland". TEDx Conference, Houston, TX, November 2010. (Oral Presentation)
2. "Nationwide Dissemination of DoseRight Syringe Clips in Swaziland: A Simple and Inexpensive Device to Ensure the Accurate Delivery of Liquid HIV/AIDS Medication". Clinton Global Initiative University Annual Meeting, San Diego, CA, April 2011. (Oral Presentation)
3. "The Last Mile: Delivering Health Technologies to the Hardest to Reach". Clinton Global Initiative University Annual Meeting, Washington, DC, March 2012 - April 2012. (Other)
4. "Single-cell Profiling of Characterization of Circulating Tumor Reactive T cells in Melanoma". National Cancer Institute, University of Pittsburgh, 2023 Inter-SPORE for Skin Cancer Meeting, Pittsburgh, PA, June 2023. (Oral Presentation)

## Peer-Reviewed Presentations Given at Meetings Not Affiliated With Yale:

### International/National

1. **Lu BY.** Nationwide Dissemination of DoseRight Syringe Clips in Swaziland: A Simple and Inexpensive Device to Ensure the Accurate Delivery of Liquid HIV/AIDS Medication. Clinton Global Initiative University Annual Meeting, San Diego, CA, April 2011. (Oral Presentation)
2. **Lu BY,** Kelly Zochowski, Shivani Thanawala, William L. Carroll, Teena Bhatla. Role of Epigenetic Modification in Childhood T-cell Acute Lymphoblastic Leukemia. Global Technology Community (GTC), Cancer Targets and Therapeutic Conference, Boston, MA, July 2014. (Oral Presentation)
3. **Lu BY,** Hailey Wyatt, Matthew Ribeiro, Tyler Stewart, Richa Gupta, Chiang V, Contessa JN, Adeniran A, Kluger H, Jilaveanu LB, Schalper K, Goldberg SB. Quantitative Evaluation of Tumor-infiltrating Lymphocyte Subsets and PD-L1 Expression in Lung Cancer Brain Metastases. Society of

- Immunotherapy for Cancer, 2018 SITC Annual Meeting, Washington, DC, November 2018. (Poster Presentation)
4. **Lu BY**, Richa Gupta, Tyler Stewart, Kluger H, Jilaveanu LB, Schalper K, Goldberg SB. Functional profile and clinical significance of major tumor infiltrating lymphocyte subsets in lung cancer-associated brain metastases. American Society of Clinical Oncology (ASCO), 2019 ASCO Annual Meeting, Chicago, IL, June 2019. (Poster Presentation)
  5. **Lu BY**, Richa Gupta, Tyler Stewart, Kluger H, Jilaveanu LB, Schalper K, Goldberg SB. Functional profile of major tumor infiltrating lymphocyte subsets and PD-L1 expression in lung cancer-associated brain metastases. International Association for the Study of Lung Cancer (IASLC), 2020 IASLC Targeted Therapies Meeting, Santa Monica, CA, February 2020. (Poster Presentation)
  6. Lewis W, **Lu BY**, Wei Wei, Liliana Lucca, Ma S, Hafler DA, Kluger H, Kluger Y. Characterizing Circulating Tumor Reactive T Cells In Metastatic Melanoma via Advanced Differential Abundance Analyses. International Society for Computational Biology, 2022 Intelligent Systems for Molecular Biology, Madison, WI, July 2022. (Poster Presentation)
  7. Robert S, **Lu BY**, Emre Kiziltug, Arnal Estape A, Nguyen D, Chiang V. Defining the Immune Profile of Radiation Necrosis through Single-cell Analysis of Intracranial Lesions. Society of Neuro-Oncology, 2022 Society of Neuro-Oncology Annual Meeting, Tampa, FL, November 2022. (Poster Presentation)
  8. Kress A, **Lu BY**, Butt A, Jana Christian, Podoltsev NA, Hurwitz ME, Goldberg SB, Burtneess BA, Isufi I, Latimore D, Lee AI, Kunz PL. Improving Diversity ,Equity, and Inclusion Education in Hematology/Oncology Training. American Society of Hematology, 2022 ASH Annual Meeting, New Orleans, LA, December 2022. (Poster Presentation)
  9. **Lu BY**, Liliana Lucca, DiStasio M, Liu Y, Giang Pham, Buitrago-Pocasangre NC, Arnal Estape A, Moliterno J, Chiang V, Omuro A, Hafler DA. Single-cell Profiling of Tumor-infiltrating Immune Cells in Human Brain Tumors. Society of Neuro-Oncology, American Society of Clinical Oncology, 2023 SNO/ASCO CNS Cancer Conference, San Francisco, CA, August 2023. (Oral Presentation)
  10. **Lu BY**, Yahsi B, Gu J, Coburn J, Kasbe MV, Arnal Estape A, Sohn K, Whitehead K, Mosharraf M, Nguyen D, Zhao H, Lucca L, Schalper K, Chiang V, Hafler DA, Lee MN. Uncovering antigen-specificity of intratumoral CD8+ T cells in non-small cell lung cancer brain metastases. Society of Neuro-Oncology and American Society of Clinical Oncology, 2025 SNO/ASCO CNS Cancer Conference, Baltimore, MD, August 2025. (Poster Presentation)
  11. Pucciarelli DM, **Lu BY**, DiStasio M. Multiplexed spatial-‘omic’ microenvironmental tumor assessment via PhenoCycler of metastatic non-small cell lung cancer to the brain. Rutgers Cancer Institute, International Brain Tumor Symposium, New Brunswick, NJ, September 2025. (Poster Presentation)
  12. Savion Gaiger N, **Lu BY**, Schoenfeld D. Tumor reactive T cells may be harvested from malignant pleural effusions. Society for Immunotherapy of Cancer Annual Meeting, National Harbor, MD, November 2025. (Poster Presentation)
  13. **Lu BY**. TIL-guided discovery of TCRs targeting epitopes derived from dark antigens and application to cancer immunotherapies. Society for Immunotherapy of Cancer, National Harbor, MD, November 2025 - January 2026. (Poster Presentation)
  14. **Lu BY**. Uncovering differences in local and systemic immunity in human primary and metastatic brain tumors. Society of NeuroOncology / World Federation of Neuro-Oncology Societies Annual Meeting, Honolulu, HI, November 2025. (Poster Presentation)

## Professional Service:

### Peer Review Groups/Grant Study Sections

|                |                                                                                         |
|----------------|-----------------------------------------------------------------------------------------|
| 2025 - Present | Reviewer, Yale Cancer Center, Leslie Warner Postdoctoral Fellowship for Cancer Research |
| 2025 - Present | Ad-hoc reviewer, Cancer Research Wales                                                  |

### Journal Services

#### *Editorial boards*

|                |                                                               |
|----------------|---------------------------------------------------------------|
| 2022 - Present | Ad-hoc mentored reviewer, Journal of ImmunoTherapy for Cancer |
| 2022 - Present | Ad-hoc mentored reviewer, Cancer Discovery                    |
| 2023 - Present | Ad-hoc mentored reviewer, Science                             |
| 2023 - Present | Ad-hoc mentored reviewer, Nature Communications               |

#### *Reviewer*

|                |                                        |
|----------------|----------------------------------------|
| 2022 - Present | Reviewer, Seminars in Immunopathology  |
| 2025 - Present | Reviewer, Journal of Clinical Oncology |
| 2025 - Present | Reviewer, Science Advances             |
| 2026 - Present | Reviewer, British Journal of Cancer    |
| 2026 - Present | Reviewer, BMC Medicine                 |

### Professional Organizations

#### *American Society of Clinical Oncology*

|                |                                               |
|----------------|-----------------------------------------------|
| 2018 - Present | Member, American Society of Clinical Oncology |
|----------------|-----------------------------------------------|

#### *International Association for the Study of Lung Cancer*

|             |                                                                |
|-------------|----------------------------------------------------------------|
| 2019 - 2020 | Member, International Association for the Study of Lung Cancer |
|-------------|----------------------------------------------------------------|

#### *Janeway Society*

|                |                         |
|----------------|-------------------------|
| 2024 - Present | Member, Janeway Society |
|----------------|-------------------------|

#### *Society for Immunotherapy of Cancer*

|                |                                             |
|----------------|---------------------------------------------|
| 2018 - Present | Member, Society for Immunotherapy of Cancer |
|----------------|---------------------------------------------|

#### *Society of Neuro-Oncology*

|                |                                   |
|----------------|-----------------------------------|
| 2025 - Present | Member, Society of Neuro-Oncology |
|----------------|-----------------------------------|

## Yale University / Hospital System

### Medical School

|                |                                                                                 |
|----------------|---------------------------------------------------------------------------------|
| 2021 - 2022    | Committee Member, Yale University, Yale Cancer Center Director Search Committee |
| 2025 - Present | Interviewer, Yale Dermatology Residency Program                                 |
| 2025 - Present | Interviewer, Yale Neurology Residency Program                                   |

## Bibliography:

### Peer-Reviewed Original Research

1. Murakami Y, Lu B, Kazaoui S, Minami N, Okubo T, Maruyama S. Photoluminescence sidebands of carbon nanotubes below the bright singlet excitonic levels. *Phys. Rev. B* 79, 195407.
2. Natoli R, Responde D, **Lu B**, Athanasiou K. Effects of multiple chondroitinase ABC applications on tissue engineered articular cartilage. *Journal Of Orthopaedic Research®* 2009, 27: 949-956. [PMID: 19123232](#), [PMCID: PMC2819396](#), [DOI: 10.1002/jor.20821](#).
3. Murakami Y, **Lu B**, Kazaoui S, Minami N, Okubo T, Maruyama S. Photoluminescence sidebands of carbon nanotubes below the bright singlet excitonic levels. *Physical Review B* 2009, 79: 195407. [DOI: 10.1103/physrevb.79.195407](#).
4. Hároz E, Rice W, **Lu B**, Ghosh S, Hauge R, Weisman R, Doorn S, Kono J. Enrichment of Armchair Carbon Nanotubes via Density Gradient Ultracentrifugation: Raman Spectroscopy Evidence. *ACS Nano* 2010, 4: 1955-1962. [PMID: 20302343](#), [DOI: 10.1021/nn901908n](#).
5. Hároz E, Duque J, **Lu B**, Nikolaev P, Arepalli S, Hauge R, Doorn S, Kono J. Unique Origin of Colors of Armchair Carbon Nanotubes. *Journal Of The American Chemical Society* 2012, 134: 4461-4464. [PMID: 22239488](#), [DOI: 10.1021/ja209333m](#).
6. Spiegel G, Dinh C, Gutierrez A, Lukomnik J, **Lu B**, Shah K, Slough T, Yeh P, Mirabal Y, Gray L, Marton S, Adler M, Schutze G, Wickham H, Oden M, Richards-Kortum R. Design, Evaluation, and Dissemination of a Plastic Syringe Clip to Improve Dosing Accuracy of Liquid Medications. *Annals Of Biomedical Engineering* 2013, 41: 1860-1868. [PMID: 23471817](#), [DOI: 10.1007/s10439-013-0780-z](#).
7. Neumann O, Feronti C, Neumann A, Dong A, Schell K, **Lu B**, Kim E, Quinn M, Thompson S, Grady N, Nordlander P, Oden M, Halas N. Compact solar autoclave based on steam generation using broadband light-harvesting nanoparticles. *Proceedings Of The National Academy Of Sciences Of The United States Of America* 2013, 110: 11677-11681. [PMID: 23836642](#), [PMCID: PMC3718182](#), [DOI: 10.1073/pnas.1310131110](#).
8. Henslee A, Yoon D, **Lu B**, Yu J, Arango A, Marruffo L, Seng L, Anver T, Ather H, Nair M, Piper S, Demian N, Wong M, Kasper F, Mikos A. Characterization of an injectable, degradable polymer for mechanical stabilization of mandibular fractures. *Journal Of Biomedical Materials Research Part B Applied Biomaterials* 2014, 103: 529-538. [PMID: 24934595](#), [DOI: 10.1002/jbm.b.33216](#).
9. **Lu B**, Kudlowitz D, Gardner L. Clinical and laboratory characteristics associated with a high optical density anti-platelet factor 4 ELISA test. *Journal Of Blood Medicine* 2015, 6: 277-283. [PMID: 26640392](#), [PMCID: PMC4657791](#), [DOI: 10.2147/jbm.s90179](#).
10. **Lu B**, Thanawala S, Zochowski K, Burke M, Carroll W, Bhatla T. Decitabine enhances chemosensitivity of early T-cell precursor-acute lymphoblastic leukemia cell lines and patient-derived samples. *Leukemia & Lymphoma* 2016, 57: 1938-1941. [PMID: 26726842](#), [DOI: 10.3109/10428194.2015.1110747](#).

11. Cavalli FMG, Hübner JM, Sharma T, Luu B, Sill M, Zapotocky M, Mack SC, Witt H, Lin T, Shih DJH, Ho B, Santi M, Emery L, Hukin J, Dunham C, McLendon RE, Lipp ES, Gururangan S, Grossbach A, French P, Kros JM, van Veelen MC, Rao AAN, Giannini C, Leary S, Jung S, Faria CC, Mora J, Schüller U, Alonso MM, Chan JA, Klekner A, Chambless LB, Hwang EI, Massimino M, Eberhart CG, Karajannis MA, **Lu B**, Liao LM, Zollo M, Ferrucci V, Carlotti C, Tirapelli DPC, Tabori U, Bouffet E, Ryzhova M, Ellison DW, Merchant TE, Gilbert MR, Armstrong TS, Korshunov A, Pfister SM, Taylor MD, Aldape K, Pajtler KW, Kool M, Ramaswamy V. Heterogeneity within the PF-EPN-B ependymoma subgroup. *Acta Neuropathologica* 2018, 136: 227-237. [PMID: 30019219](#), [PMCID: PMC6373486](#), [DOI: 10.1007/s00401-018-1888-x](#).
12. Lucca LE, Axisa PP, **Lu B**, Harnett B, Jessel S, Zhang L, Raddassi K, Zhang L, Olino K, Clune J, Singer M, Kluger HM, Hafler DA. Circulating clonally expanded T cells reflect functions of tumor-infiltrating T cells. *Journal Of Experimental Medicine* 2021, 218: e20200921. [PMID: 33651881](#), [PMCID: PMC7933991](#), [DOI: 10.1084/jem.20200921](#).
13. Tran TT, Rane CK, Zito CR, Weiss SA, Jessel S, Lucca L, **Lu BY**, Oria VO, Adeniran A, Chiang VL, Omay SB, Hafler DA, Kluger HM, Jilaveanu LB. Clinical Significance of PDCD4 in Melanoma by Subcellular Expression and in Tumor-Associated Immune Cells. *Cancers* 2021, 13: 1049. [PMID: 33801444](#), [PMCID: PMC7958624](#), [DOI: 10.3390/cancers13051049](#).
14. **Lu BY**, Gupta R, Aguirre-Ducler A, Gianino N, Wyatt H, Ribeiro M, Chiang VL, Contessa JN, Adeniran AJ, Jilaveanu LB, Kluger HM, Schalper KA, Goldberg SB. Spatially resolved analysis of the T cell immune contexture in lung cancer-associated brain metastases. *Journal For ImmunoTherapy Of Cancer* 2021, 9: e002684. [PMID: 34670827](#), [PMCID: PMC8529973](#), [DOI: 10.1136/jitc-2021-002684](#).
15. Lu B, Lucca L, DiStasio M, Liu Y, Pham G, Buitrago-Pocasangre N, Arnal-Estape A, Moliterno J, Chiang V, Omuro A, Hafler D. BSBM-18 SINGLE-CELL PROFILING TUMOR-INFILTRATING IMMUNE CELLS REVEALS CXCL13+ FOLLICULAR HELPER-LIKE CD4+ T CELLS IN HUMAN BRAIN TUMORS. *Neuro-Oncology Advances* 2023, 5: iii4-iii4. [PMCID: PMC10402449](#), [DOI: 10.1093/noajnl/vdad070.014](#).
16. Butt A, Christian J, Kress A, **Lu B**, Hurwitz M, Goldberg S, Podoltsev N, Gilkes L, Lee A. Providing 0.1 Full-Time Equivalent (FTE) Support to Fellowship Core Faculty Improves Faculty Involvement in Fellowship Education and Recruitment. *Journal Of Cancer Education* 2024, 39: 325-334. [PMID: 38430454](#), [PMCID: PMC12279297](#), [DOI: 10.1007/s13187-024-02414-z](#).
17. Schoenfeld D, Djureinovic D, Su D, Zhang L, **Lu B**, Kanga L, Mann J, Huck J, Hurwitz M, Braun D, Jilaveanu L, Ring A, Kluger H. Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti-CTLA-4 in renal cell carcinoma. *JCI Insight* 2024, 10: e184545. [PMID: 39561007](#), [PMCID: PMC11721305](#), [DOI: 10.1172/jci.insight.184545](#).
18. **Lu B**, Lucca L, Lewis W, Wang J, Nogueira C, Heer S, Rayon-Estrada V, Axisa P, Reeves S, Buitrago-Pocasangre N, Pham G, Kojima M, Wei W, Aizenbud L, Bacchiocchi A, Zhang L, Walewski J, Chiang V, Olino K, Clune J, Halaban R, Kluger Y, Coyle A, Kisielow J, Obermair F, Kluger H, Hafler D. Circulating tumor-reactive KIR+CD8+ T cells suppress anti-tumor immunity in patients with melanoma. *Nature Immunology* 2024, 26: 82-91. [PMID: 39609626](#), [PMCID: PMC12285569](#), [DOI: 10.1038/s41590-024-02023-4](#).
19. Yoshida T, Nguyen M, Zhang L, **Lu B**, Zhu B, Murray K, Mineur Y, Zhang C, Xu D, Lin E, Luchsinger J, Bhatta S, Waizman D, Coden M, Ma Y, Israni-Winger K, Russo A, Wang H, Song W, Al Souz J, Zhao H, Craft J, Picciotto M, Grutzendler J, Distasio M, Palm N, Hafler D, Wang A. The subfornical organ is a

- nucleus for gut-derived T cells that regulate behaviour. *Nature* 2025, 643: 499-508. [PMID: 40437096](#), [PMCID: PMC12768464](#), [DOI: 10.1038/s41586-025-09050-7](#).
20. Gaiger NS, Coburn J, Zhang L, Nolan N, Woodard G, Kluger HM, et al. 381 Tumor reactive T cells may be harvested from malignant pleural effusions. *Journal for ImmunoTherapy of Cancer*. 2025;13:. <https://doi.org/10.1136/jitc-2025-SITC2025.0381>
  21. Nogueira C, Heer S, Rayon-Estrada V, Brenner J, Mehta N, Drescher T, Dong J, Shambharkar P, Cereghetti-Terraneo N, Loi M, Renoux F, Malia T, Wille M, Carey S, Swain J, Lu B, Kluger H, Hafler D, Pregibon D, Hurwitz A, Kisielow J, Obermair FJ, Coyle A. 2025;13:. [https://jitc.bmj.com/content/13/Suppl\\_2/A1125](https://jitc.bmj.com/content/13/Suppl_2/A1125)
  22. Gaiger NS, Coburn J, Lee MN, Zhang L, Chen H, Woodard GA, Kluger HM, Schoenfeld DA, Lu BY. *bioRxiv* 2025.12.05.692662; doi: <https://doi.org/10.64898/2025.12.05.692662>
  23. Lu B, Yahsi B, Lucca L, DiStasio M, Liu Y, Gu J, Bhata, S, Kasbe M, Coburn J, Arnal-Estape A, Zhao H, Moliterno J, Chiang V, Omuro A, Lee M, Hafler D. *Neuro-Oncology*, 27;Suppl\_5, Nov 2025, v222–v223, <https://doi.org/10.1093/neuonc/noaf201.0883>
  24. Vilariño N, de Rodas M, Villalba-Esparza M, Rajendran B, Huang B, Hijazo-Pechero S, Costantini A, Ranjan K, Ramos-Paradas J, **Lu B**, Nadal E, Goldberg S, Nguyen D, Schalper K. NSCLC brain metastases exhibit reduced HLA-I antigen presentation machinery and immune evasion independent of IFN $\gamma$  signaling defects. *Molecular Cancer* 2026 [PMID: 42210261](#), [DOI: 10.1186/s12943-026-02687-6](#).
  25. Agesta A, Ferrand C, Le Dorze AL, Peillex C, Carrié N, Barascud R, Palak A, Esteban L, Bernal T, Joulia E, Colacios C, Pereira TM, Perocheschi R, Pichler A, Chaubet A, Zahm M, Saoudi A, El Costa H, Adoue V, Lu BY, Lucca LE, Martinet L, Dejean AS. The transcription factor Eomes drives a stemness program in CD4(+) T cells that promotes anti-tumor immunity in response to immunotherapy. *Immunity* 2026 [PMID: 42341755](#), [DOI: 10.1016/j.immuni.2026.05.018](#).

#### Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements

1. Stahl M, **Lu BY**, Kim TK, Zeidan AM. Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock? *Targeted Oncology* 2017, 12: 413-447. [PMID: 28664386](#), [DOI: 10.1007/s11523-017-0503-8](#).
2. Eguren-Santamaria I, Sanmamed MF, Goldberg SB, Kluger HM, Idoate MA, **Lu B**, Corral J, Schalper KA, Herbst RS, Gil-Bazo I. PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice. *Clinical Cancer Research* 2020, 26: 4186-4197. [PMID: 32354698](#), [DOI: 10.1158/1078-0432.ccr-20-0798](#).
3. Pauken KE, Lagattuta KA, **Lu BY**, Lucca LE, Daud AI, Hafler DA, Kluger HM, Raychaudhuri S, Sharpe AH. TCR-sequencing in cancer and autoimmunity: barcodes and beyond. *Trends In Immunology* 2022, 43: 180-194. [PMID: 35090787](#), [PMCID: PMC8882139](#), [DOI: 10.1016/j.it.2022.01.002](#).
4. Pucciarelli D, **Lu B**, Zlobec I, DiStasio M. Beyond the Lab and Into the Hospital: An Outlook on the Clinical Utility of Spatial Omics Technologies. *GEN Biotechnology* 2023, 2: 360-371. [DOI: 10.1089/genbio.2023.0030](#).
5. Lu BY, Goldberg SB. Medical management of non-small cell lung cancer brain metastases in the modern era. 2026. *Cancer J*. In press.

## Peer-Reviewed Case Reports and Technical Notes

1. Haynes M, **Lu B**, Winkel A. Ovarian Vein Thrombophlebitis Related to Large Uterine Myoma. *Obstetrics And Gynecology* 2014, 123: 450-453. [PMID: 24413242](#), [DOI: 10.1097/aog.0000000000000091](#).
2. Bhatla T, Dandekar S, **Lu B**, Wang J, Han E, Bitterman D, Jones C, Evensen N, Magid M, Meyer J, Carroll W. Genomic Characterization of Poorly Differentiated Neuroendocrine Carcinoma in a Pediatric Patient. *Journal Of Pediatric Hematology/Oncology* 2016, 38: e21-e25. [PMID: 26558807](#), [PMCID: PMC4681625](#), [DOI: 10.1097/mpb.0000000000000463](#).
3. **Lu B**, Kojima L, Huang M, Friedmann A, Ferry J, Weinstein H. Facial manifestations of Epstein–Barr virus-related lymphoproliferative disease in childhood acute lymphoblastic leukemia in remission: Two atypical presentations. *Pediatric Blood & Cancer* 2016, 63: 2042-2045. [PMID: 27392033](#), [DOI: 10.1002/pbc.26102](#).
4. Madhusoodhan P, **Lu B**, Chen J, Jones C, Meyer J, Roman E, Nardi M, Carroll W, Bhatla T. Splice site mutation in factor X gene manifesting as severe intracranial haemorrhage in neonatal period with a challenging treatment course. *Haemophilia* 2016, 23: e138-e140. [PMID: 27995737](#), [DOI: 10.1111/hae.13138](#).
5. **Lu BY**, Isitan C, Mahajan A, Chiang V, Huttner A, Mitzner JR, Wesley SF, Goldberg SB. Intracranial Complications From Immune Checkpoint Therapy in a Patient With NSCLC and Multiple Sclerosis: Case Report. *JTO Clinical And Research Reports* 2021, 2: 100183. [PMID: 34590030](#), [PMCID: PMC8474265](#), [DOI: 10.1016/j.jtocrr.2021.100183](#).

## Chapters

1. Kaulen LD, Lu BY, Goldberg SB, Baehring JM, Chapter 15 - Neurological complications of lung cancer, Editor(s): Herbert B. Newton, Mark G. Malkin, *Neurological Complications of Systemic Cancer and Antineoplastic Therapy (Second Edition)*, Academic Press, 2022, Pages 243-276, DOI: 10.1016/b978-0-12-821976-8.00027-x

## Commentaries, Editorials and Letters

1. **Lu B**, Goldberg S. Chemoimmunotherapy for Untreated Lung Cancer Brain Metastases: Systemic Before Local Therapy? *Journal Of Clinical Oncology* 2023, 41: 4462-4464. [PMID: 37603819](#), [DOI: 10.1200/jco.23.01323](#).